Search results for "CGM"
showing 3 items of 33 documents
TREATMENT WITH SILDENAFIL PREVENTS IMPAIRMENT OF LEARNING IN RATS BORN TO PRE-ECLAMPTIC MOTHERS
2010
Pre-eclampsia is an important hypertensive pregnancy disorder and a main cause of maternal and fetal morbidity and mortality Children born from mothers with preeclampsia may present cognitive deficits The mechanisms leading to this cognitive impairment remain unclear and no treatments to improve it have been tested Pre-eclampsia is associated with impaired regulation of the nitric oxide 3 5 guanosine monophosphate cyclic (cGMP) pathway, which modulates some cognitive functions We hypothesized that alterations in the NO-cGMP pathway would be involved in the mechanisms leading to cognitive impairment in rats born to pre-eclamptic mothers and that treatment with sildenafil an inhibitor of the …
Nitric oxide synthases: regulation and function
2011
Nitric oxide (NO), the smallest signalling molecule known, is produced by three isoforms of NO synthase (NOS; EC 1.14.13.39). They all utilize l-arginine and molecular oxygen as substrates and require the cofactors reduced nicotinamide-adenine-dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and (6R-)5,6,7,8-tetrahydrobiopterin (BH(4)). All NOS bind calmodulin and contain haem. Neuronal NOS (nNOS, NOS I) is constitutively expressed in central and peripheral neurons and some other cell types. Its functions include synaptic plasticity in the central nervous system (CNS), central regulation of blood pressure, smooth muscle relaxation, and vasodila…
Atherosclerosis: risk assessment and the role of aiming for optimal glycaemic control in young patients with type 1 diabetes
2023
Wprowadzenie: Dzieci z cukrzycą typu 1 (type 1 diabetes mellitus – DM1) mają w porównaniu ze zdrowymi rówieśnikami podwyższone ryzyko rozwoju zaawansowanej miażdżycy oraz choroby sercowo-naczyniowej (cardiovascular disease – CVD), a niedostateczna kontrola glikemii jest najważniejszym modyfikowalnym czynnikiem ryzyka CVD w DM1. Aktualne metody oceny kontroli glikemii to ocena hemoglobiny glikowanej (HbA1c), samokontrola glikemii za pomocą glukometru (SMBG), a także stosowanie systemów ciągłego monitorowania glukozy (CGM). Do pośredniej oceny ryzyka rozwoju CVD mogą służyć badania rozszerzenia tętnicy w odpowiedzi na niedokrwienie (flow-mediated dilatation – FMD) i prędkości fali tętna (PWV)…